



May 22, 2024

BSE Limited Corporate Relationship Department Phiroze Jeejeebhoy Towers Dalal Street, Fort Mumbai 400 001 Scrip Code: 512529	National Stock Exchange of India Limited Listing Department Exchange Plaza, Bandra-Kurla Complex Bandra (East) Mumbai – 400 051 Symbol: SEQUENT
--	---

Dear Sir/ Madam,

Subject: Re-submission – Outcome dated February 05,2024 – your email dt. May 21, 2024

Ref: Outcome of Board Meeting held on February 05, 2024

Pursuant to Regulation 30 (read with Part A of Schedule III) of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 ('SEBI LODR'), we would like to inform you that the Board of Directors at its Meeting held on February 05, 2024, *inter-alia*, considered and approved the following:

1. Notice of Postal Ballot for seeking Members approval,
 - a. To create security on the undertakings of the Company under Section 180(1)(a) of the Companies Act, 2013 and,
 - b. To consider and approve the divestment by the Company of its shareholding and beneficial interest in material subsidiary of the Company and to approve sale, disposal, and lease of assets exceeding 20% of the assets of the material subsidiaries of the Company pursuant to the provisions of Regulation 24(5) & 24(6) of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

No entity/ unit/ undertaking has been sold. The transaction involves pledge of shares of Alivira Animal Health Limited, India (WOS of the Company), by the Company for the borrowing arrangement with Barclays Bank PLC.

Find attached as Annexure-A our disclosure in terms of the SEBI Circular No. SEBI/HO/CFD/CFD-PoD-1/P/CIR/2023/123 dated 13th July 2023.

SeQuent Scientific Limited

Registered Office: 301, Dosti Pinnacle, Plot No. E7, Road No. 22, Wagle Industrial Area, Thane (W), Mumbai - 400604, India

Tel: +9122 4111777 | CIN: L99999MH1985PLC036685

<http://www.sequent.in> | Email ID: investorrelations@sequent.in



The Board Meeting commenced at 11:05 AM and concluded at 11:40 AM

Kindly take the same on record

Thanking you,

Yours faithfully,
For **Sequent Scientific Limited**

Phillip Trott
Company Secretary & Compliance Officer
Membership No. F-7403

SeQuent Scientific Limited

Registered Office: 301, Dosti Pinnacle, Plot No. E7, Road No. 22, Wagle Industrial Area, Thane (W), Mumbai - 400604, India

Tel: +9122 4111777 | CIN: L99999MH1985PLC036685

<http://www.sequent.in> | Email ID: investorrelations@sequent.in



The details as required under SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 read with SEBI Circular No. SEBI/HO/CFD/CFD-PoD-1/P/CIR/2023/123 dated 13th July, 2023 are as under:

Annexture-A

Sr.No	Particulars	Details
a)	The amount and percentage of the turnover or revenue or income and net worth contributed by such unit or division or undertaking or subsidiary or associate company of the listed entity during the last financial year;	Revenue Rs. 4400.25 Mn (31%) Net worth Rs. 5190.95 Mn (24%)
b)	date on which the agreement for sale has been entered into	No entity/ unit/ undertaking has been sold. The transaction involves pledge of shares of Alivira Animal Health Limited, India (WOS of the Company), by the Company. As on date the pledge agreement in favour of Catalyst Trusteeship Limited on behalf of Barclays Bank PLC under the Banking facility agreement dated 8 th April, 2024 is entered between Alivira Animal Health Limited, India (WOS), Alivira Animal Health Limited, Ireland (SDS) and Barclays Bank PLC
c)	The expected date of completion of sale/disposal	There is no sale. The shares are pledged as per the share pledge agreement dated 8 th April 2024.
d)	Consideration received from such sale/disposal.	Not Applicable, since there is no sale of assets, and it is only pledge of shares as security under the borrowing arrangement with Barclays Bank PLC

SeQuent Scientific Limited

Registered Office: 301, Dosti Pinnacle, Plot No. E7, Road No. 22, Wagle Industrial Area, Thane (W), Mumbai - 400604, India

Tel: +9122 4111777 | CIN: L99999MH1985PLC036685

<http://www.sequent.in> | Email ID: investorrelations@sequent.in



e)	Brief details of buyers and whether any of the buyers belong to the promoter/ promoter group/group companies. If yes, details thereof;	Same as (d)
f)	Whether the transaction would fall within related party transactions? If yes, whether the same is done at “arm’s length”;	NO
g)	Whether the sale, lease or disposal of the undertaking is outside Scheme of Arrangement? If yes, details of the same including compliance with regulation 37A of LODR Regulations.	Same as (d)
h)	Additionally, in case of a slump sale, indicative disclosures provided for amalgamation/merger, shall be disclosed by the listed entity with respect to such slump sale.	Same as (d)

SeQuent Scientific Limited

Registered Office: 301, Dosti Pinnacle, Plot No. E7, Road No. 22, Wagle Industrial Area, Thane (W), Mumbai - 400604, India

Tel: +9122 4111777 | CIN: L99999MH1985PLC036685

<http://www.sequent.in> | Email ID: investorrelations@sequent.in